GenMab News
Most Popular GenMab Story
Glaxo forges $2.1B deal for HuMax-CD20
Denmark's Genmab will gain up to $2.1 billion in a licensing deal with GlaxoSmithKline for the HuMax-CD20 antibody for leukemia, far outstripping the numbers predicted by analysts. Genmab will get $102 million up front, a 10 percent equity investment worth $357 million and up to $1.6 billion in milestone payments. The therapy is in a late-stage trial for chronic lymphocytic leukemia and non-Hodkin's lymphoma and in mid-stage trials for rheumatoid arthritis and new cases of lymphocytic …
... Read more...Latest Headlines
- August 1, 2008
- June 4, 2008
- February 21, 2008
- January 28, 2008
- November 20, 2007
- June 29, 2007
- January 3, 2007
- December 20, 2006
- December 19, 2006
- December 18, 2006
- December 7, 2006
- November 5, 2006
- October 17, 2006
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
